skip to content
CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis. Preview this item
ClosePreview this item
Checking...

CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.

Author: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
Publisher: [Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health, June 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English : Version 1.0
Summary:
The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, if the following conditions are met: conditions: patient under the care of a specialist with  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1089416273
Notes: "Final."
Description: 1 online resource (1 PDF file (7 pages)).
Series Title: Common drug review clinical review report.
Other Titles: Daclizumab (Zinbryta -- Biogen Canada Inc.)
Drug reimbursement recommendation Daclizumab (Zinbryta)

Abstract:

The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, if the following conditions are met: conditions: patient under the care of a specialist with experience in the diagnosis and management of RRMS; reduction in price of at least 25%.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1089416273> # CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "1089416273" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/multiple_sclerosis_relapsing_remitting_drug_therapy> ; # Multiple Sclerosis, Relapsing-Remitting--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_therapeutic_use> ; # Daclizumab--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_administration_&_dosage> ; # Daclizumab--administration & dosage
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/insurance_health_reimbursement_economics> ; # Insurance, Health, Reimbursement--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_economics> ; # Daclizumab--economics
    schema:alternateName "Daclizumab (Zinbryta -- Biogen Canada Inc.)" ;
    schema:alternateName "Drug reimbursement recommendation Daclizumab (Zinbryta)" ;
    schema:author <http://experiment.worldcat.org/entity/work/data/8961824911#Organization/cadth_canadian_drug_expert_committee> ; # CADTH Canadian Drug Expert Committee,
    schema:bookEdition "Version 1.0." ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8961824911#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, if the following conditions are met: conditions: patient under the care of a specialist with experience in the diagnosis and management of RRMS; reduction in price of at least 25%."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8961824911> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8961824911#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8961824911#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:name "CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis."@en ;
    schema:productID "1089416273" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK535204/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1089416273> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8961824911#Organization/cadth_canadian_drug_expert_committee> # CADTH Canadian Drug Expert Committee,
    a schema:Organization ;
    schema:name "CADTH Canadian Drug Expert Committee," ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1089416273> ; # CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1089416273> ; # CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_administration_&_dosage> # Daclizumab--administration & dosage
    a schema:Intangible ;
    schema:name "Daclizumab--administration & dosage"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_economics> # Daclizumab--economics
    a schema:Intangible ;
    schema:name "Daclizumab--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/daclizumab_therapeutic_use> # Daclizumab--therapeutic use
    a schema:Intangible ;
    schema:name "Daclizumab--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/insurance_health_reimbursement_economics> # Insurance, Health, Reimbursement--economics
    a schema:Intangible ;
    schema:name "Insurance, Health, Reimbursement--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961824911#Topic/multiple_sclerosis_relapsing_remitting_drug_therapy> # Multiple Sclerosis, Relapsing-Remitting--drug therapy
    a schema:Intangible ;
    schema:name "Multiple Sclerosis, Relapsing-Remitting--drug therapy"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1089416273>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1089416273> ; # CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.
    schema:dateModified "2020-01-18" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.